Insulin growth factor-1 (IGF-1) is an important survival and growth factor in multiple myeloma (MM) 1 and various other malignancies, 2 and its receptor (IGF-1R) has been recently shown to be an ideal therapeutic target. 3 Few studies have examined IGF-1R and IGF-1 expression in MM patients. To better understand the distribution of the receptor in myeloma, we decided to perform a detailed study of its expression using gene expression profiling.
We investigated the mRNA expression of IGF-1 and IGF-1R in normal and malignant plasma cells (PC) as part of gene expression profiling studies in PC from 15 normal individuals and 147 patients with various PC neoplasm (22 monoclonal gammopathy of undetermined significance (MGUS), 24 smoldering MM (SMM) and 101 symptomatic MM). Of the 101 MM cases, 72 were newly diagnosed and 29 were relapsed cases. The samples were all collected under informed consent and the study was approved by the Mayo Clinic Institutional Review Board. Bone marrow aspirates were enriched for PCs using CD138 þ immunomagnetic bead selection. Total RNA was extracted, converted to biotinylated cRNA and hybridized to Letters to the Editor U133A gene chips (Affymetrix, Santa Clara, CA, USA). Gene expression intensity values were log transformed, normalized to the median and analyzed using GeneSpring 7 (Silicon Genetics, Redwood City, CA, USA). Patients were then classified according to expression of seven genes (FGFR3, MMSET, ITGB7, MAF, CCND3, CCND1 and CCND2) as previously described. 4 This gene expression-based molecular classification (TC classification) accurately identifies all the major cytogenetic categories in MM: t(4;14)(p16;q32) (based on FGFR3/MMSET expression); t(14;16)(q32;q23) and t(14;20) (based on expression of ITGB7 and MAF); t(6;14) assessed by high level of CCND3 expression; t(11;14)(q13;q32) based on high level of CCND1 expression; hyperdiploid MM based of aberrant low level of CCND1 expression or low D1 with high D2 expression (D1 þ D2 group). Two other TC groups, high CCND2 but no CCND1 expression (D2 group) or no CCND1 or 2 expression (none group), are biologically ill-defined. Fluorescent in situ hybridization (FISH) analysis for 13q deletion (D13) and IgH translocations was also performed as previously described. 5 Nonparametric tests were used for statistical analysis. For comparison of gene expression level between multiple groups, the Kruskal-Wallis test is used with Dunn's multiple testing correction for pair-wise comparisons. For comparison between two groups, the Mann-Whitney U-test is used. The distribution for overall survival (OS) was estimated using the method of Kaplan and Meier. The log-rank test was used to test for differences in survival between groups. OS was calculated from day of sampling to death. P-values of o0.05 is considered significant.
We first measured the level of expression of IGF-1R. While the median level of expression of IGF-1R is similar between normal and malignant PCs (Figure 1a) , one can clearly see cases of PC neoplasm (two MGUS, three SMM, 11 MM) with aberrant increased IGF-1R expression (exceeding mean þ 2 s.d. of expression in normal PCs). The median expression level is similar between patients with newly diagnosed disease vs those from patients with relapsed MM (data not shown). Our data suggest that expression of IGF-1R in normal PCs is consistent with the described role of the IGF signaling in PC homing to the bone marrow. 6 We next assessed IGF-1R expression by TC groups and D13 status in the 101 MM patients. When the expression of IGF-1R was assessed among the TC groups, the highest levels of expression were associated with t(4;14)(p16;q32) and maf translocation groups (Kruskal-Wallis, Po0.0001), although significant overlap exists among all categories (Figure 1b) . Our findings agree with a recent study using flow cytometry which also showed highest IGF-1R expression in tumors with these poor prognostic translocations. 7 In general, MM cases with D13 have higher IGF-1R expression (P ¼ 0.009) (Figure 1c ). This agrees with a previous gene expression study, 8 but not the flow cytometry-based study which showed no difference possibly due to a small sample size. 7 We found a similar level of IGF-1 expression between malignant and normal PCs (Figure 1d ), confirming the results of a previous ELISA-based study of serum IGF-1 in MM. 9 This suggests that IGF-1, required by the myeloma cells, may be derived from bone marrow stromal cells. We found no difference in IGF-1 expression levels between the different TC groups and patients with or without D13 (data not shown).
We next assess the prognostic impact of IGF-1R and IGF-1 expression levels on OS of the 72 newly diagnosed MM in our cohort. The median follow-up of this cohort is 724 days and 30 of these patients have died. Using threshold expression levels of 1.5 for both IGF-1R and IGF-1 (based on mean þ 2 s.d. expression of normal PCs), no difference in OS was detected (Figure 2a and b) .
Our gene expression-based results are in agreement with previous studies measuring IGF-1R and IGF-1 protein levels by flow cytometry and ELISA respectively, 7, 9 showing good concordance between gene expression and protein data. While Letters to the Editor the absolute difference in gene expression level of IGF-1R among patients with different TC classes and D13 status is small, this can be accounted for by the log-transformation and normalization of gene expression data. Furthermore, and given the aforementioned considerations, there may be biologic relevance to such differences, particularly for cases with higher levels of expression. Our results fail to confirm the prognostic importance of IGF-1R and IGF-1 suggested by other investigators. 7, 9 This may be due to differences in the study population, the relatively shorter follow-up in our cohort or the sample size, and the limited number of events. However, it is important to note that powerful prognostic factors like t(4;14), t(14;16), D13 (Figure 2c and d) and plasma cell labeling index (data not shown) already demonstrate statistically significant prognostic impact in our cohort despite the relatively short follow-up, suggesting that IGF-1 and IGF-1R expression levels are unlikely to have important prognostic impact.
In conclusion, our study suggests there may be differential requirement for IGF-1 by the different genetic subtypes of MM as highlighted by the differential IGF-1R expression, particularly among patients with the more aggressive variants of MM. Therefore, when identifying novel targets, it is important to consider the context of genetic heterogeneity. The potential greater activity of anti-IGF-1R strategies is promising in that it addresses an unmet need, better and more durable treatment for patients with high risk MM such as those with t(4;14)(p16;q32) or t(14;16)(q32;q23).
Polymerase chain reaction (PCR)-based assays are commonly used to detect clonal immunoglobulin (IG) gene rearrangements during the evaluation of lymphocyte infiltrates. These assays are based on the following principles: B-cell precursors rearrange two or more of their six IG genes (two each IGH, IGK, IGL) during development such that each cell has a unique sequence (of unique length) in the V(D)J region (see Figure 1 , also Trainor et al 1 Coad et al 2 vanDongen et al 3 for review). Using PCR, the V(D)J regions in DNA isolated from a cell population of interest can be amplified and the size spectrum of fragments analyzed using electrophoresis. Nonrearranged genes will not amplify because the distance between primers is too great. Amplification from a polyclonal population of cells with rearranged IG genes produces fragments of varying lengths while amplification from a monoclonal population produces IG fragments of identical length. PCR-based clinical assays for IG gene rearrangement evaluation have been limited by lack of standardization and poor clinical sensitivity. 4 Poor sensitivity is generally due to the use of a limited number of consensus V region primers that fail to bind when target sequences deviate from the germ line sequence. This is usually caused by point mutations introduced during the process of somatic hyper mutation in the secondary follicle center. The sensitivity of the IG gene rearrangement assay can be improved by increasing the number of primers used and the number of genes analyzed, but this is technically challenging. Recently, an extensive set of primers for PCR-based
